Long COVID in vaccinated women with Polycystic Ovary Syndrome: A retrospective cohort pilot study
Downloads
HIGHLIGHTS
- Among women with PCOS, many still reported persistent long COVID symptoms such as hair loss and fatigue.
- COVID-19 vaccination does not exacerbate symptoms of PCOS, which further emphasizes the importance of completing COVID-19 doses for women with PCOS to avoid long COVID sequelae.
ABSTRACT
Objective: Long COVID, or the persistence of symptoms after acute COVID-19 illness, can affect individuals with pre-existing health conditions such as polycystic ovary syndrome (PCOS). Long COVID and PCOS may share overlapping pathogenesis which potentially exacerbate one another. The aim of this study was to evaluate the symptoms of long COVID in women with PCOS who have been vaccinated and investigate whether COVID-19 vaccination or infection worsened PCOS symptoms.
Materials and Methods: We carried out a retrospective cohort study on 44 women with PCOS who have been vaccinated and previously diagnosed with COVID-19. Questionnaires were distributed to find out the effect of COVID infection and vaccines in these women, as well as the symptoms of long COVID-19.
Results: Of all participants, 28 women (70%) continued to report persistent long COVID symptoms, with the highest number of complaints being fatigue and hair loss. The results, using Mann-Whitney test, showed that there was no difference in PCOS symptoms before and after COVID-19 vaccination (p = 0.520) or after COVID-19 infections (p = 0.241). Although this study revealed a substantial prevalence of long COVID symptoms among women with PCOS, an encouraging finding emerged: neither the administration of COVID-19 vaccination nor prior infection with COVID-19 had a significant impact on PCOS-associated symptoms.
Conclusion: This study further underscores the importance of vaccination for all individuals, including women with a history of PCOS. Furthermore, the purpose of COVID-19 vaccination is to mitigate symptom severity, thus potentially diminishing the occurrence of long-term COVID-19 symptoms in future cases.
Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27–36.
Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–75.
Burhan E (2022) Long COVID: diagnosis and treatment of respiratory syndrome in post COVID-19 conditions. Jurnal Respirologi Indonesia 42(3):250–6.
Kenny G, Townsend L, Savinelli S, Mallon PWG (2023) Long COVID: clinical characteristics, proposed pathogenesis and potential therapeutic targets. Front Mol Biosci 10:1157651.
de Medeiros SF, Yamamoto MMW, de Medeiros MAS, Yamamoto AKLW, Barbosa BB (2022) Polycystic ovary syndrome and risks for COVID-19 infection: a comprehensive review. Rev Endocr Metab Disord 23(2):251–64.
Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P (2021) Long COVID risk - a signal to address sex hormones and women's health. Lancet Reg Health Eur 11:100242.
Atkinson L, Kite C, McGregor G, James T, Clark CCT, Randeva HS, et al (2021) Uncertainty, anxiety and isolation: experiencing the COVID-19 pandemic and lockdown as a woman with polycystic ovary syndrome (PCOS). J Pers Med 11(10):952.
Kite C, Atkinson L, McGregor G, Clark CCT, Brown JE, Kyrou I, et al (2021) Sleep disruption and depression, stress and anxiety levels in women with polycystic ovary syndrome (PCOS) during the lockdown measures for COVID-19 in the UK. Front Glob Womens Health 2:649104.
Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS (2020) Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic. BMC Med 18(1):220.
Morgante G, Troí¬a L, De Leo V (2021) Coronavirus Disease 2019 (SARS-CoV-2) and polycystic ovarian disease: Is there a higher risk for these women? J Steroid Biochem Mol Bio 205:105770.
Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW (2020) TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov 10(6):779–82.
Sah P, Fitzpatrick MC, Zimmer CF, et al (2021) Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci U S A 118:e2109229118.
Kalidhindi RSR, Borkar NA, Ambhore NS, Pabelick CM, Prakash YS, Sathish V (2020) Sex steroids skew ACE2 expression in human airway: a contributing factor to sex differences in COVID-19? Am J Physiol Lung Cell Mol Physiol 319(5): L843-L847.
Yassin A, Sabsigh R, Al-Zoubi RM, Aboumarzouk OM, Alwani M, Nettleship J, et al (2023) Testosterone and Covid-19: an update. Reviews in Medical Virology 33(1):e2395.
Moin ASM, Sathyapalan T, Atkin SL, Butler AE (2020) Renin-angiotensin system overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection? Metabol Open 7:100052.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
